Lupin Limited has announced an exciting new launch in the United States: Rivaroxaban for Oral Suspension, 1 mg/mL. This medicine is bioequivalent to Xarelto® Oral Suspension, 1 mg/mL from Janssen Pharmaceuticals, meaning it works the same way in the body.
Rivaroxaban for Oral Suspension is designed to help children and teens with specific blood clot conditions. Its uses include:
-
Treating blood clots (venous thromboembolism, or VTE) and reducing the risk of them coming back in children from birth up to 18 years old, after initial treatment with other anticoagulants.
-
Preventing blood clots in kids aged 2 and above with congenital heart disease following the Fontan procedure.
This formulation (equivalent to Xarelto®) is already a well-known treatment in the U.S., with estimated annual sales of around USD 11 million as of July 2025 (IQVIA MAT).
With this launch, Lupin continues to expand its presence in the U.S. market and provide important treatment options for pediatric patients in need of anticoagulant therapy.
